By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Tuesday, 17 Nov 2026
Donate to The Mirror
Masvingo Mirror
  • Local News
  • Politics
  • Business
  • Sports
  • Health
  • Travel
  • Agriculture
  • Opinion
  • More
    • Lifestyle
    • Technology
    • Education
    • Religion
    • Community
    • Crime
    • International
    • Zim Universities/College Research Projects
My News
Latest News
Runde RDC to dispose off 8 old vehicles
From a Tomato Garden, US$300 at Uni, Courts: Samantha Chidodo’s Triumph Over Child Marriage
War veterans to hold liberation songs symposium
Teacher dragged to court for canning student
SA Border Management Authority holds 3rd conference tomorrow
Masvingo MirrorMasvingo Mirror
Font ResizerAa
  • Read History
  • Environment
  • Business
  • Politics
  • Finance
  • Technology
Search
  • Pages
    • Home
    • Blog Index
    • Contact Us
    • Search Page
    • 404 Page
  • Personalized
    • Read History
  • Categories
    • Business
    • Politics
    • Technology
    • Environment
    • Finance
Have an existing account? Sign In
Follow US
© 2022 Foxiz News Network. Ruby Design Company. All Rights Reserved.
Health

Bringing Diagnostics To The People

mv_admin
Last updated: 25 December 2024 7:09 am
By
mv_admin
Share
16 Min Read
SHARE

…Breaking Barriers To Access

Masvingo Mirror Health Correspondent, Catherine Murombedzi had an opportunity to interview Mr Shiva Sriram, President of Business Development at Molbio Diagnostics. Late diagnosis of diseases results in poor treatment outcomes. A clarion call to bring quality, innovative diagnostic tools to the people also requires support to the users of these tools. Mr Sriram envisions a future of accurate disease detection. He called on countries to adopt cutting edge tools with artificial intelligence (AI) aided approach.

Q: What is Molbio Diagnostics’ mission? What do you intend to achieve as Molbio?

A: Molbio Diagnostics’ mission is to bring healthcare closer to people through quality diagnostics. We aim to ensure that no individual across the globe, regardless of their socioeconomic background or geography, is left unattended regarding healthcare. Today, globally, nearly 80% of the total population in lower-middle-income countries still has little or no access to healthcare, specifically diagnostics.

Thus, Molbio Diagnostics, through its cutting edge innovation, ensures that these solutions can reach the last mile so that nobody has to suffer or lose their life due to a lack of access to diagnostics.

Q: At COP29, Molbio Diagnostics donated innovative diagnostic tools to Azerbaijan. Could you please speak on that?

Mentally challenged children’s home in crisis
Wadyajena nabbed in Cottco scandal
Chikanga youth get nutrition training
Zim vaccinates 40 percent of population

A: Azerbaijan hosted COP29 this year in Baku. For the first time, one of the events organized at COP29 focused on demonstrating the connection between climate change and tuberculosis. The Stop TB Partnership Geneva highlighted how changing climate patterns could lead to an increase in malnutrition, food insecurity, migration, and population density—all factors that exacerbate the tuberculosis crisis. This was the first time such issues were showcased by the Stop TB Partnership at a COP event. The Azerbaijan government was very keen on adopting the “TB Go Green” campaign. With new innovative tools like Truenat and portable X-ray machines, screening and diagnostics can be decentralized, ensuring early access for care. Molbio believes that such initiatives need to be supported in every way possible.

We donated the Prorad ATLAS Ultraportable X-ray system, the Truenat rapid molecular diagnostics platform, and the Truelux solar charging station to Azerbaijan to support their climate-resilient campaign. Azerbaijan has committed to ensuring that its elimination targets can be met. More importantly, the country has already transitioned over 95% from microscopy to rapid molecular testing. Despite this transition, they realize that the molecular testing currently in use is still largely centralized. There is now an opportunity to decentralize with Truenat, which was the objective of the donation.

Q: I attended the Goa TB conference in May 2024, where we were taken around the Molbio premises. It’s a state-of-the-art facility; could you please speak more about that?

A: When manufacturing healthcare products and medical devices, it is extremely important to be quality-conscious. We have built very strong quality management systems in our organization to ensure that the products we deliver are consistent and meet the standards set by the company. We operate state-of-the-art manufacturing facilities with teams dedicated to execution, complemented by other support functions like quality control and quality assurance.

We also have a separate logistics team focused on dispatches and a distinct sales and marketing function operating from headquarters. It’s a multifunctional team that ensures the entire product journey—from research and development (R&D) to manufacturing scale and delivery to the customer—maintains consistency and quality.

Q. India has a high TB burden, which was a focus of our conference. Southern Africa also experiences a significant TB burden. Laboratories often take time to process and send results. Could you tell us about molecular testing and the benefits of using Truenat?

A:  Truenat is a point-of-care rapid molecular diagnostic platform. Molecular diagnostics, and specifically real-time PCR, is a technology that has been around for many decades and is known to be the most accurate way of diagnosing infectious diseases. However, until recently, the challenge with molecular testing has been its limited accessibility, as molecular tools have always been confined to highly centralized facilities requiring complex infrastructure, manpower, and resources that were not available across all geographies. This made it highly inaccessible.

With Truenat, we have miniaturized real-time PCR into a small, portable, simple, battery-operated solution that requires minimal training and infrastructure to conduct tests. These devices can now be deployed in very remote, underserved, and hard-to-reach areas. They are portable and can be taken right to the primary care level, enabling early diagnosis and intervention, allowing diseases to be detected more easily. Patients can now be screened upfront with a molecular test, rather than using it merely as a confirmatory tool as in the past. With Truenat, we have created a battery-operated solution that can run for an entire day on a full charge, even in places with limited access to electricity.

In locations without electricity, we also provide a solar solution. Truenat can now be charged through a simple, portable solar panel, making it independent of infrastructure and available wherever there is a need, so that people do not have to travel long distances to get diagnosed. They can now access this technology right at their doorstep.

Q: That’s wonderful—it’s like bringing diagnostics directly to the people. Once someone has been tested, how long does it take for the results to come out?

A: Truenat delivers results within one hour of sample processing. Once a patient visits a health center and provides a sample, they can be diagnosed within an hour and immediately placed on precise, evidence-based treatment the same day.

Q: That is a game-changer because traditionally, TB diagnosis could take a week or more, during which time a patient’s condition might deteriorate. What is the average cost of having that mobile unit for the Truenat?

A: Truenat consists of a combination of devices, which represent the capital infrastructure, and the chip, which is a consumable. The device costs approximately between US$12,000 and US$14,000. The cost per test for tuberculosis (TB), which has been globally negotiated by the Global Fund and USAID, is US$7.9 per test. All countries around the world can avail themselves of these prices for the deployment of Truenat in public health settings.

Q. That’s even more cost-effective if we are now at $7 per diagnosis. How do you support countries in the event of equipment breakdown?

A: We have a robust network of distributors across the countries we operate in. These distributors employ service engineers and application specialists who are fully trained to install and service our machines within the country. We typically invite these service providers to India for training.

They undergo an extensive 10 to 15-day training session on servicing, conducted by our team here. This training ensures that when they return to the field, they are fully equipped to independently service the machines.

Q: Countries could go for days waiting for someone from the manufacturer to come for repairs. Thank you for addressing that. What is the average lifespan of the gadget?

A: While we claim that Truenat machines, like any other, have an average lifespan of about five to seven years, many of them have been operational for over 10 years without any issues. The main reason for this reliability is the absence of moving parts, unlike many other machines.

Truenat is a solid-state device with minimal breakdown and no need for annual calibrations, especially when deployed in remote areas, which is a significant advantage. However, the battery could potentially degrade over time, but it is a replaceable component. Despite this, devices have been running in the field for over 10 years without a single battery change, proving their ruggedness.

Q: What other innovative tools is Molbio developing?

A: There are two parts to this answer. First, in the field of tuberculosis, because of Truenat, patients can now avail of a molecular test upfront. This largely caters to symptomatic patients who seek care at healthcare centers, which is known as passive case finding.

However, if we aim to eliminate TB by 2030, we must also initiate active case finding, wherein contacts of patients, their communities, and families are also screened for TB. Practically, this is not feasible with a molecular test alone. You need a tool like a digital X-ray to conduct the screening.

Digital X-rays are typically large pieces of equipment available only in centralized facilities. Molbio has developed an ultra-portable digital X-ray called the ProRad Atlas, which is a small, compact, battery-operated device that can be hand-carried to screening camps. It can be deployed at the primary care level and used for mass population screening to identify asymptomatic TB cases.

Then, those found positive can be referred to Truenat. This is the solution we are offering now as an end-to-end platform with the X-ray and Truenat for TB. Beyond these solutions, we have also diversified into providing breast cancer screening at the point of care.

Breast cancer is a major issue, being the leading cause of cancer death in women, primarily due to delayed diagnosis. The only way breast cancer is screened today is through mammography, which is not a scalable tool. Only symptomatic patients are typically subjected to a mammogram. Our solution, called Thermalytics, can be deployed in remote locations without the need for any infrastructure.

Thermalytics is a pain-free, touch-free, and discreet screening tool that ensures complete privacy for the patient and involves no radiation. Within 10 minutes, a patient can sit in front of the device, and an AI-generated report indicates the status of breast cancer in the patient, allowing for further action. This tool is a mass screening device that can be taken to the point of care to help screen for breast cancer at a very early stage of the disease.

Q. Regarding the portable X-ray machine and no-touch features, many women who have undergone a mammogram can attest to its discomfort due to the clamps compressing the breast. It’s an unpleasant experience. Do you supply the cartridges and the accessories?

A: Truenat is a technology entirely developed and conceptualised by Molbio. It is a closed system. We supply both the machines and the cartridges. While the platform is built for multiple diseases, TB has been a key focus. Once these machines are in a healthcare center, they can diagnose multiple infectious diseases.

The same machine can test for hepatitis, malaria, dengue, HIV, and more. It is a multi-disease, multi-function platform that can process a variety of sample types, from sputum and blood to stool, urine, and tissues. This versatility makes it a multi-utility platform that can strengthen the healthcare system once deployed.

Q: Indeed, it’s multipurpose—a one-stop diagnosis center where you just change the cartridge. Do you have any programs with universities?

A: We are engaged in multiple outreach programs. We work with universities to provide students with internship opportunities at our research & department facilities. We have recently launched an innovation accelerator program called EDGE, where we invite start-up companies working on healthcare technologies and innovations to collaborate with us.

We go through a selection process and provide complete end-to-end support, whether financial or technical mentorship, to bring their products and innovations to commercialization and then further to scale. This is part of our efforts to collaborate with both private startups and universities and agencies focusing on healthcare R&D.

Q: Your donation to Azerbaijan was a noble gesture. With climate change and increased disease transmission, we see that science and innovation can help reduce and mitigate effects. Given the dynamics and rapid changes, especially during COVID when no one was safe, could you please share your thoughts on this?

A: The key message is to work in a collaborative, multi-stakeholder manner as much as possible. It is clear from the COVID-19 experience that no single agency can take complete ownership of providing universal access to healthcare. NGOs, civil society, bureaucracy, governments, politicians, and the private sector all have roles to play. Unless all these stakeholders collaborate and work in a manner where we have a clear pathway and vision for disease eradication, it will never be possible to eliminate some of these public health challenges that are currently impacting us and many more that may arise with the on-going climate change concerns. Thus, a collaborative, multi-stakeholder approach is the only way forward.

CALL TO ACTION 

In conclusion, the One Health aspect requires collaborative efforts.

Countries are urged to invest in AI-aided diagnostic technologies, ensuring that healthcare systems are equipped to tackle emerging health challenges. By embracing innovation and adopting AI-powered diagnostic tools, we can create a future where disease detection is more accurate, efficient, and effective.

Multi-stakeholder collaboration between health communities, civil society organisations, the media, researchers, and medical doctors is the key to decentralising access to healthcare and diagnostics.

Feedback: [email protected]

Mother appeals for help to save son needing urgent spine surgery
AI, Computer-Aided Detection Boost TB Diagnosis in Africa
Gumba kumba Club on land grabbing spree
Cholera outbreak: Mkoba Teachers College temporarily closed 
Unsung Heroes/Heroines: A Patient’s Tribute to Caregivers
Share This Article
Email Copy Link Print
Previous Article Bhaso holds Auxilia Chimusoro memorial 
Next Article Fundhouse director scoops Megafest award
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Recipe Rating




- Advertisement -

You May also Like

Health

Stop self-diagnosis, googling for answers – Kwekwe health workers told

19 March 2024
Health

Embracing Healthy Lifestyle Changes and Supporting Stroke Survivors: A Call to Action

31 October 2024
Health

The Race Against Time: Understanding PEP

6 July 2026
Health

Breast cancer survivors warn against ‘bush doctors’

17 November 2024
Show More
  • More News:
  • ZANU PF
  • July Moyo
  • Emmerson Mnangagwa
  • CCC
  • Citizens Coalition for Change
  • Tendai Biti
  • Kudakwashe Dhewa
  • Nelson Chamisa
  • Zvishavane
  • ZEC
  • Douglas Mwonzora
  • Mutevekwi River
  • Winston Chitando
  • Gutsaruzhinji
  • Larry Mavima
  • Tongogara Rural District Council
  • Masvingo United
  • Chamisa
  • EMA
  • Unki Mine
Masvingo Mirror

The Independent Paper for Masvingo and the Southern Region

Youtube Medium Rss

About Company

  • About us
  • Advertise with US
  • Complaint
  • Privacy Policy
  • Cookie Policy
  • Submit a Tip
Subscribe Now for Real-time Updates on the Latest Stories!
© 2026 Masvingo Mirror. All Rights Reserved.
Welcome to Foxiz
Username or Email Address
Password

Lost your password?